Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 965Urinary Bladder Neoplasms 268Carcinoma, Renal Cell 253Kidney Neoplasms 146Breast Neoplasms 131Carcinoma, Transitional Cell 127Neoplasms 122Colorectal Neoplasms 100Ovarian Neoplasms 93Melanoma 85Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 83Neoplasm Metastasis 79Pancreatic Neoplasms 69Non-Muscle Invasive Bladder Neoplasms 68Uterine Cervical Neoplasms 59Stomach Neoplasms 56Head and Neck Neoplasms 52Endometrial Neoplasms 50Squamous Cell Carcinoma of Head and Neck 48Esophageal Neoplasms 44Adenocarcinoma 44Testicular Neoplasms 42Carcinoma, Hepatocellular 41Sarcoma 39Triple Negative Breast Neoplasms 34Liver Neoplasms 32Disease 31Colonic Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25

Interventions

testosterone enanthate 1testosterone 17 beta-cypionate 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Castration Resistant Metastatic Prostate Cancer × Genitourinary × Clear all
NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡